NCT04615013 2025-10-30
NBTXR3, Chemotherapy, and Radiation Therapy for the Treatment of Esophageal Cancer
M.D. Anderson Cancer Center
Phase 1 Recruiting
Clinical Trials
9 trialsNCT05238831 2024-01-23
SMMART Adaptive Clinical Treatment (ACT) Trial
OHSU Knight Cancer Institute
Phase EARLY_PHASE1 Withdrawn
NCT04508686 2021-01-29
Combination of Metronomic Capecitabine With Camrelizumab for Treatment of Refractory Solid Tumor Trial (Cohort 1)
Ruijin Hospital
Phase 1 Unknown
NCT00354601 2017-08-30
Docetaxel and Capecitabine in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cavity Cancer
Wake Forest University Health Sciences
Phase 2 Terminated
NCT00003704 2016-07-06
Chemotherapy Plus Radiation Therapy in Treating Patients With Unresectable, Residual, or Recurrent Colorectal Cancer
Alliance for Clinical Trials in Oncology
Phase 1 Completed
NCT00403429 2016-01-14
MITO-6: Capecitabine in Platinum Resistant Ovarian Cancer
National Cancer Institute, Naples
Phase 2 Completed
NCT00004012 2013-06-24
Capecitabine in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00257348 2013-02-08
Capecitabine and Docetaxel in Advanced/Recurrent Cervical Cancer
University of California, Irvine
Phase 2 Completed
NCT00118300 2011-07-08
Capecitabine and Radiation Therapy in Treating Patients With Locally Advanced Cervical Cancer or Other Pelvic Cancer
Case Comprehensive Cancer Center
Phase 1 Withdrawn